Saturday, October 26

Making Your Mark with Private Label Vitamins and Supplements (non-CE)

Saturday, October 26
4:00-5:30 p.m.

Supplements and vitamins are a nearly $37 billion industry and, for pharmacies, one of the largest profit margin producers. Are you taking full advantage of these OTCs at your pharmacy?  It’s time to put a stop to sales slipping to retail sharks on the internet. With a private label, these products will point customers to your home page.  Learn from a panel of experts what it means to have a private label, how they began to develop their own brand, and how this has impacted their practice and profits. It’s time to bust the myths surrounding private label products. This category isn’t just for some, it’s for all!

 Walk away with:

  • An understanding of what it means to carry a private label and why it is important for your business.
  • Examples of pharmacists who have had different levels of adoption for private labels.
  • Ideas for how you can integrate a private label into your practice.


Josh Rimany, RPh, FACA, owner, Dilworth Drug and Wellness Center. Recognizing that his patients were heading to Amazon to buy the same vitamins he was selling, Josh Rimany decided to intervene by making a label they could only get from him  – his own.  Creating a private label has allowed Josh to create brand loyalty and ensure that the profits from supplement sales would stay within his four walls.

Kathy Campbell, PharmD, owner, Medicap Pharmacy. Developing a private label in her single-pharmacist practice allows Kathy Campbell to ensure that when she works with patients to achieve optimal health, they can walk out of store with her product in hand and keep coming back for more.  Kathy’s expansion into private label products has allowed her to improve her patients’ health and the pharmacy’s supplement profits.

Gabe Trahan, NCPA senior director of store operations and marketing. Gabe Trahan has worked with hundreds of community pharmacies of all sizes to help them improve their image and ultimately boost front-end profits. From conducting in-store and virtual consultations to presenting at educational workshops and writing extensively on front-end retailing, Gabe has established himself as the leading expert in effective and innovative front-end design and merchandising.

Implementing Pharmacogenomics in your Business

Saturday, October 26
4:00-5:00 p.m. followed by a non-CE Shoot the Breeze from 5-5:30 p.m.

It’s no longer a futuristic concept, but a practice reality. With more than 200 drugs with genomic information in their FDA approved package inserts, understanding these drug-gene interactions is just as important as understanding drug-drug or drug-food interactions. Adding pharmacogenomic services to your community or long-term care pharmacy is an opportunity to optimize patients’ therapy and add revenue to your bottom line. Discover the relationships, workflow pearls, and marketing plans that your peers have implemented to make it work.

Walk away with:

  • A how-to guide for implementing a pharmacogenomic service tomorrow.
  • A checklist for identifying and vetting pharmacogenomic lab partnerships.
  • A marketing plan for relationship-building with patients, providers, and group homes.


Amina Abubakar, PharmD, AAHIVP, owner, RxClinic Pharmacy, Charlotte, N.C. Amina is a leader in community pharmacy, always finding a way to implement new services into her business and advance the profession. She has cracked the code and is operating a successful pharmacogenomics program. Amina is an advocate in this space and was recently invited to the White House Office of Science and Technology Policy and to the FDA to discuss the role of pharmacists in pharmacogenomics.

Pharmacist and Pharmacy Technician Learning Objectives:

  1. List strategies for marketing to and building relationships with other health care professionals who could provide enhanced patient care with pharmacogenomic information.
  2. Describe different ways of implementing pharmacogenomic services that benefit your patients and business.
  3. Identify opportunities to determine which patients may be eligible to receive pharmacogenomic services.